American Physiology Summitt

by EpicentRx | May 7, 2024 | Conferences, General

April 2024 – Long Beach, California Learn more

American Association for Cancer Research (AACR)

by EpicentRx | May 7, 2024 | Conferences

April 2024 – San Diego, California Poster Session: Improved clinical outcomes in patients received treatment beyond tumor progression with AdAPT-001 +/- a checkpoint inhibitor Learn more

A licence to kill

by EpicentRx | May 7, 2024 | Media

EpicentRx to Present Positive Phase 2a Clinical Data with its AdAPT-001 TGF-β Trap Program in Checkpoint Inhibitor Resistant Patients at the 2024 AACR Meeting

by EpicentRx | Apr 4, 2024 | 2024, Press Releases

Compelling clinical data demonstrate that AdAPT-001, which delivers a TGF-β trap to tumors, reverses established resistance to checkpoint inhibitors and makes checkpoint inhibitors more active SAN DIEGO, April 2, 2024 /PRNewswire/ — EpicentRx, Inc, a...

Q1 and Not Done

by EpicentRx | Apr 1, 2024 | Company Updates

This being a leap year, EpicentRx leapt into action in Q1. In January, which is named after the two-faced Roman God, Janus, who focused simultaneously on the past and the future, EpicentRx made sure to look back even as it moved forward. February, the leap month, was...